This technology is a set of methodologies for the characterization and enhancement of the efficacy of CD8+ T cells for therapeutic use.
The preparation of immune cells, such as CD8+ T cells, outside of the body for subsequent implantation is a promising technique for the treatment of cancer, viral infections, and bacterial infections. However, there is currently a lack of accurate methods that can reliably predict the efficacy of these cells prior to administering them into patients, limiting their overall use and effectiveness. As such, a substantial need exists to develop methods for predicting the potential therapeutic benefit of ex-vivo expanded immune cells prior to implantation in patients.
This technology comprises methods for the characterization and the enhancement of the efficacy of CD8+ T cells for therapeutic use. Using collagen-fibrin gels in combination with clonogenic assays, reliable determination of active CD8+ T cell quantity and quality can be used to predict efficacy in treating neoplastic, viral, and bacterial infections. By supporting the growth of both the cytotoxic T cell and various diseased cells, this assay enables researchers to determine the efficacy of select immune cells and effectively assess their therapeutic potential. As such, this technology has the potential to greatly enhance the capabilities of CD8+ T cells as a potential therapeutic agent.
IR 2856, 2860
Licensing Contact: Sara Gusik